Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anxo Pharmaceutical CoROCO:6677 +0.88%66 FCF Margin % is 6.89% as of Dec. 2025, which is 191% above its 10-year median of 2.37. GuruFocus rates ROCO:6677 with a GF Score™ of 66/100 and a GF Value™ of NT$30.26 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 963 Drug Manufacturers companies, Anxo Pharmaceutical Co ranks worse than 55.56% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anxo Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anxo Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anxo Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Anxo Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anxo Pharmaceutical Co (ROCO:6677) has a FCF Margin % of 6.89% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Anxo Pharmaceutical Co and its competitors. This is 191% above median its historical median of 2.37. According to the industry distribution chart, Anxo Pharmaceutical Co ranks #535 out of 963 companies in the Drug Manufacturers industry, placing it in the top 55.6%.
Is Anxo Pharmaceutical Co's FCF Margin % too high?
Anxo Pharmaceutical Co's current FCF Margin % of 6.89% is 191% above median its 10-year median of 2.37. The Drug Manufacturers industry median FCF Margin % is 2.57. Anxo Pharmaceutical Co's value of 6.89% is 168.1% above this industry median. Based on the distribution chart, Anxo Pharmaceutical Co ranks #535 out of 963 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anxo Pharmaceutical Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anxo Pharmaceutical Co ranks #535 out of 963 companies for FCF Margin %. This places Anxo Pharmaceutical Co in the lower half of its industry. The industry median FCF Margin % is 2.57. Anxo Pharmaceutical Co's value of 6.89% is 168.1% above this benchmark. While the company's 10-year median is 2.37 vs. the industry median of 2.57, Anxo Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anxo Pharmaceutical Co's current FCF Margin % of 6.89% is 168.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Anxo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anxo Pharmaceutical Co's current FCF Margin % is 6.89%, which is 191% above median its own 10-year median of 2.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.26, compared to a current price of NT$17.20 — trading 43.2% below its estimated fair value. The current FCF Margin % is 6.89%, which is 191% above median its 10-year median of 2.37 and 168.1% above the Drug Manufacturers industry median of 2.57. Anxo Pharmaceutical Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current FCF Margin % is 6.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$17.20 is trading 43.2% below its estimated GF Value™ of NT$30.26.
GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.
Key valuation signals for ROCO:6677:
FCF Margin %: 6.89% (191% above median its 10-year median of 2.37)
GF Value™: NT$30.26 vs. price of NT$17.20 (43.2% below fair value)
Industry Position: 168.1% above the Drug Manufacturers median (#535 of 963)
No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
66GF Score
Get the complete analysis for ROCO:6677
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6677 has been successfully added to your 
